





Age-standardised difference between proportional effects  
in single agent / polychemotherapy:  $\chi^2_1 = 5.6$ ;  $2p = 0.02$



■ 99% or ◊ 95% confidence intervals

0 0.5 1.0 1.5 2.0  
Chemotherapy better | Chemotherapy worse


Age-standardised difference between proportional effects  
in single agent / polychemotherapy:  $\chi_1^2 = 7.7$ ;  $2p = 0.006$




■ 99% or ◊ 95% confidence intervals

0 0.5 1.0 1.5 2.0  
Chemotherapy better | Chemotherapy worse


Age-standardised difference between proportional effects  
in single agent / polychemotherapy:  $\chi^2_1 = 7.5$ ;  $2p = 0.006$




Age-standardised difference between proportional effects in single agent / polychemotherapy:  $\chi_1^2 = 0.4$ ; 2p > 0.1; NS




Age-standardised difference between proportional effects in single agent / polychemotherapy:  $\chi_1^2 = 1.3$ ;  $2p > 0.1$ ; NS



Age-standardised difference between proportional effects  
in single agent / polychemotherapy:  $\chi_1^2 = 0.3$ ; 2p > 0.1; NS




Age-standardised difference between proportional effects  
in single agent / polychemotherapy:  $\chi_1^2 = 3.7$ ;  $2p = 0.05$



Age-standardised difference between proportional effects  
in single agent / polychemotherapy:  $\chi^2_1 = 3.3$ ;  $2p = 0.07$







■ 99% or ◊ 95% confidence intervals

0 0.5 1.0 1.5 2.0  
Chemotherapy better | Chemotherapy worse


Age-standardised difference between proportional effects  
in single agent / polychemotherapy:  $\chi_1^2 = 3.7$ ;  $2p = 0.06$



Age-standardised difference between proportional effects  
in single agent / polychemotherapy:  $\chi_1^2 = 0.07$ ;  $2p > 0.1$ ; NS




Age-standardised difference between proportional effects  
in single agent / polychemotherapy:  $\chi_1^2 = 0.7$ ; 2p > 0.1; NS



■ 99% or ◊ 95% confidence intervals


0 0.5 1.0 1.5 2.0  
Chemotherapy better | Chemotherapy worse

Age-standardised difference between proportional effects in single agent / polychemotherapy:  $\chi_1^2 = 1.2$ ;  $2p > 0.1$ ; NS




Recurrence rates (% / year) and logrank analyses

	Years 0 – 4	Years 5 – 9	Years 10 – 14	Year 15+
Polychemo.	6.17 (887 / 14365)	3.17 (257 / 8095)	1.85 (59 / 3183)	2.32 (25 / 1078)
Control	9.47 (1172 / 12378)	3.78 (240 / 6346)	2.26 (53 / 2340)	3.10 (22 / 710)
Rate ratio, from	0.59 SE 0.04	0.79 SE 0.08	0.76 SE 0.18	0.63 SE 0.29
(O-E) / V	-227.8 / 429.4	-25.9 / 110.1	-6.4 / 23.8	-3.6 / 7.9




Death rates (% / year: total rate – rate in women without recurrence) & logrank analyses

	Years 0 – 4	Years 5 – 9	Years 10 – 14	Year 15+
Polychemo.	3.39 (3.55 – 0.16)	2.98 (3.20 – 0.22)	1.58 (2.19 – 0.61)	1.70 (2.40 – 0.70)
Control	4.35 (4.53 – 0.18)	4.08 (4.24 – 0.16)	2.31 (2.64 – 0.33)	2.54 (2.86 – 0.32)
Rate ratio, from	0.74 SE 0.05	0.68 SE 0.07	0.62 SE 0.14	0.46 SE 0.21
(O-E) / V	-77.0 / 259.3	-51.4 / 135.9	-15.0 / 31.0	-8.8 / 11.3



Death rates (% / year) and logrank analyses


	Years 0 – 4	Years 5 – 9	Years 10 – 14	Year 15+
Polychemo.	3.55 (555 / 15642)	3.20 (298 / 9316)	2.19 (87 / 3964)	2.40 (42 / 1751)
Control	4.53 (657 / 14497)	4.24 (340 / 8020)	2.64 (84 / 3177)	2.86 (34 / 1188)
Rate ratio, from	0.74 SE 0.05	0.70 SE 0.07	0.75 SE 0.14	0.60 SE 0.21
(O-E) / V	-79.2 / 268.6	-50.5 / 142.1	-10.9 / 37.3	-6.8 / 13.5



Recurrence rates (% / year) and logrank analyses


	Years 0 – 4	Years 5 – 9	Years 10 – 14	Year 15+
Polychemo.	7.08 (2827 / 39918)	4.89 (932 / 19049)	3.54 (184 / 5196)	2.66 (32 / 1204)
Control	9.04 (2836 / 31376)	4.84 (690 / 14265)	3.79 (153 / 4035)	5.00 (50 / 1000)
Rate ratio, from	0.77 SE 0.03	0.99 SE 0.05	0.94 SE 0.11	0.50 SE 0.18
(O-E) / V	-317.4 / 1190.4	-2.6 / 352.2	-4.6 / 73.5	-10.6 / 15.2






Death rates (% / year: total rate – rate in women without recurrence) & logrank analyses

	Years 0 – 4	Years 5 – 9	Years 10 – 14	Year 15+
Polychemo.	3.95 (4.46 – 0.51)	4.37 (5.29 – 0.92)	3.65 (5.29 – 1.64)	2.64 (4.28 – 1.64)
Control	4.59 (5.08 – 0.49)	4.78 (5.87 – 1.09)	4.35 (5.56 – 1.21)	2.95 (4.76 – 1.81)
Rate ratio, from	0.86 SE 0.03	0.91 SE 0.05	0.87 SE 0.09	1.01 SE 0.21
(O-E) / V	-115.5 / 749.2	-39.0 / 426.5	-15.4 / 113.7	0.2 / 23.7




Death rates (% / year) and logrank analyses

	Years 0 – 4	Years 5 – 9	Years 10 – 14	Year 15+
Polychemo.	4.46 (1939 / 43481)	5.29 (1205 / 22766)	5.29 (350 / 6618)	4.28 (80 / 1867)
Control	5.08 (1815 / 35729)	5.87 (1051 / 17898)	5.56 (305 / 5483)	4.76 (84 / 1766)
Rate ratio, from	0.87 SE 0.03	0.90 SE 0.04	0.95 SE 0.08	0.96 SE 0.17
(O-E) / V	-111.1 / 824.5	-51.2 / 496.5	-7.5 / 142.9	-1.4 / 33.4




Recurrence rates (% / year) and logrank analyses

	Years 0 – 4	Years 5 – 9	Year 10+
Polychemo.	3.99 (383 / 9598)	2.49 (140 / 5630)	1.76 (36 / 2042)
Control	6.53 (575 / 8809)	3.18 (151 / 4748)	2.38 (42 / 1766)
Rate ratio, from (O-E) / V	0.59 SE 0.05 -114.8 / 221.0	0.78 SE 0.11 -17.1 / 68.8	0.77 SE 0.21 -4.7 / 17.5




Death rates (% / year: total rate – rate in women without recurrence) & logrank analyses

	Years 0 – 4	Years 5 – 9	Year 10+
Polychemo.	1.86 (1.97 – 0.11)	1.99 (2.20 – 0.21)	0.96 (1.35 – 0.39)
Control	2.62 (2.73 – 0.11)	2.51 (2.64 – 0.13)	1.50 (1.78 – 0.20)
Rate ratio, from (O–E) / V	0.70 SE 0.08 –38.8 / 107.6	0.77 SE 0.11 –16.6 / 64.5	0.60 SE 0.20 –8.2 / 15.9




Death rates (% / year) and logrank analyses

	Years 0 – 4	Years 5 – 9	Year 10+
Polychemo.	1.97 (201 / 10216)	2.20 (138 / 6276)	1.35 (37 / 2742)
Control	2.73 (270 / 9879)	2.64 (153 / 5786)	1.78 (45 / 2531)
Rate ratio, from (O-E) / V	0.71 SE 0.08 -38.3 / 112.1	0.81 SE 0.11 -14.8 / 68.7	0.70 SE 0.19 -6.7 / 19.0




Recurrence rates (% / year) and logrank analyses

	Years 0 – 4	Years 5 – 9	Year 10+
Polychemo.	11.14 (494 / 4433)	4.74 (114 / 2407)	2.16 (48 / 2225)
Control	17.68 (591 / 3343)	5.56 (87 / 1564)	2.55 (33 / 1293)
Rate ratio, from (O-E) / V	0.59 SE 0.05 -112.6 / 214.3	0.81 SE 0.14 -8.9 / 42.2	0.77 SE 0.22 -4.2 / 16.1



Death rates (% / year: total rate – rate in women without recurrence) & logrank analyses


	Years 0 – 4	Years 5 – 9	Year 10+
Polychemo.	6.61 (6.83 – 0.22)	5.06 (5.32 – 0.26)	2.20 (3.09 – 0.89)
Control	8.39 (8.76 – 0.37)	8.21 (8.47 – 0.26)	3.45 (3.96 – 0.51)
Rate ratio, from (O–E) / V	0.77 SE 0.07 –40.0 / 154.2	0.62 SE 0.09 –35.6 / 74.0	0.60 SE 0.15 –14.3 / 27.9



Death rates (% / year) and logrank analyses


	Years 0 – 4	Years 5 – 9	Year 10+
Polychemo.	6.83 (347 / 5081)	5.32 (158 / 2970)	3.09 (92 / 2977)
Control	8.76 (384 / 4385)	8.47 (186 / 2197)	3.96 (73 / 1843)
Rate ratio, from (O-E) / V	0.76 SE 0.07 -42.7 / 158.9	0.62 SE 0.09 -36.3 / 76.0	0.74 SE 0.15 -10.0 / 33.6






Recurrence rates (% / year) and logrank analyses

	Years 0 – 4	Years 5 – 9	Year 10+
Polychemo.	3.11 (389 / 12508)	2.70 (180 / 6666)	3.09 (58 / 1874)
Control	4.42 (527 / 11917)	2.73 (167 / 6107)	3.15 (51 / 1621)
Rate ratio, from (O-E) / V	0.69 SE 0.06 -79.7 / 214.7	1.00 SE 0.11 -0.1 / 82.3	0.94 SE 0.20 -1.4 / 23.5




Death rates (% / year: total rate – rate in women without recurrence) & logrank analyses

	Years 0 – 4	Years 5 – 9	Year 10+
Polychemo.	1.48 (1.82 – 0.34)	2.03 (2.72 – 0.69)	1.72 (2.45 – 0.73)
Control	2.11 (2.40 – 0.29)	2.28 (3.13 – 0.85)	2.17 (2.78 – 0.61)
Rate ratio, from (O–E) / V	0.69 SE 0.08 –41.3 / 110.7	0.89 SE 0.11 –8.6 / 76.5	0.76 SE 0.18 –6.2 / 22.4




Death rates (% / year) and logrank analyses

	Years 0 – 4	Years 5 – 9	Year 10+
Polychemo.	1.82 (238 / 13057)	2.72 (199 / 7325)	2.45 (62 / 2528)
Control	2.40 (307 / 12776)	3.13 (216 / 6891)	2.78 (65 / 2336)
Rate ratio, from (O-E) / V	0.76 SE 0.08 -36.4 / 129.9	0.87 SE 0.09 -14.0 / 98.5	0.82 SE 0.17 -5.6 / 28.8




Recurrence rates (% / year) and logrank analyses

	Years 0 – 4	Years 5 – 9	Year 10+
Polychemo.	9.00 (2420 / 26881)	6.07 (749 / 12341)	3.48 (158 / 4540)
Control	12.09 (2279 / 18851)	6.45 (521 / 8077)	4.43 (152 / 3429)
Rate ratio, from (O-E) / V	0.79 SE 0.03 -232.3 / 970.7	0.99 SE 0.06 -2.4 / 272.3	0.80 SE 0.11 -15.3 / 68.5




Death rates (% / year: total rate – rate in women without recurrence) & logrank analyses

	Years 0 – 4	Years 5 – 9	Year 10+
Polychemo.	5.09 (5.67 – 0.58)	5.48 (6.51 – 1.03)	4.10 (6.16 – 2.06)
Control	6.10 (6.70 – 0.60)	6.36 (7.62 – 1.26)	4.81 (6.58 – 1.77)
Rate ratio, from (O–E) / V	0.90 SE 0.04 –69.3 / 638.4	0.91 SE 0.05 –31.3 / 350.8	0.91 SE 0.09 –11.9 / 119.7




Death rates (% / year) and logrank analyses


	Years 0 – 4	Years 5 – 9	Year 10+
Polychemo.	5.67 (1695 / 29879)	6.51 (1003 / 15396)	6.16 (368 / 5971)
Control	6.70 (1495 / 22325)	7.62 (832 / 10920)	6.58 (324 / 4923)
Rate ratio, from (O-E) / V	0.90 SE 0.04 -71.2 / 694.7	0.91 SE 0.05 -38.7 / 400.4	0.96 SE 0.08 -5.6 / 154.2




\* Isolated contralateral recurrence as first event. (N.B. contralateral analyses in Table 2 and its Appendix are more complete, as they include additional trials).












\* Isolated contralateral recurrence as first event. (N.B. contralateral analyses in Table 2 and its Appendix are more complete, as they include additional trials).









Recurrence rates (% / year) and logrank analyses

	Years 0 – 4	Years 5 – 9	Year 10+
Polychemo.	6.28 (220 / 3504)	1.83 (38 / 2077)	1.06 (14 / 1319)
Control	10.92 (303 / 2775)	2.41 (37 / 1537)	1.79 (18 / 1004)
Rate ratio, from (O-E) / V	0.58 SE 0.07 -60.5 / 111.9	0.80 SE 0.22 -3.6 / 16.5	0.66 SE 0.30 -3.0 / 7.2




Death rates (% / year: total rate – rate in women without recurrence) & logrank analyses

	Years 0 – 4	Years 5 – 9	Year 10+
Polychemo.	3.69 (3.95 – 0.26)	1.39 (1.82 – 0.43)	0.70 (1.04 – 0.34)
Control	5.35 (5.67 – 0.22)	2.49 (2.62 – 0.13)	0.70 (1.33 – 0.63)
Rate ratio, from (O–E) / V	0.70 SE 0.10 –25.9 / 73.3	0.59 SE 0.17 –10.5 / 19.8	0.82 SE 0.37 –1.2 / 6.1



Death rates (% / year) and logrank analyses


	Years 0 – 4	Years 5 – 9	Year 10+
Polychemo.	3.95 (151 / 3822)	1.82 (43 / 2368)	1.04 (18 / 1725)
Control	5.67 (189 / 3331)	2.62 (51 / 1947)	1.33 (19 / 1425)
Rate ratio, from (O-E) / V	0.71 SE 0.10 -25.9 / 76.1	0.66 SE 0.18 -9.0 / 21.3	0.73 SE 0.30 -2.5 / 8.1



Recurrence rates (% / year) and logrank analyses


	Years 0 – 4	Years 5 – 9	Year 10+
Polychemo.	3.25 (166 / 5109)	2.77 (82 / 2956)	2.84 (12 / 423)
Control	4.74 (219 / 4616)	3.28 (82 / 2502)	5.16 (16 / 310)
Rate ratio, from (O-E) / V	0.61 SE 0.09 -42.0 / 84.7	0.81 SE 0.15 -8.1 / 37.7	0.51 SE 0.30 -4.1 / 6.0






Death rates (% / year: total rate – rate in women without recurrence) & logrank analyses

	Years 0 – 4	Years 5 – 9	Year 10+
Polychemo.	1.73 (1.91 – 0.18)	1.72 (2.30 – 0.58)	1.83 (2.51 – 0.68)
Control	2.14 (2.49 – 0.35)	2.22 (2.74 – 0.52)	2.15 (3.76 – 1.61)
Rate ratio, from (O–E) / V	0.67 SE 0.12 –18.2 / 46.1	0.70 SE 0.15 –11.5 / 31.9	0.55 SE 0.37 –2.4 / 4.1




Death rates (% / year) and logrank analyses

	Years 0 – 4	Years 5 – 9	Year 10+
Polychemo.	1.91 (102 / 5331)	2.30 (73 / 3171)	2.51 (13 / 517)
Control	2.49 (124 / 4979)	2.74 (78 / 2844)	3.76 (14 / 372)
Rate ratio, from (O-E) / V	0.69 SE 0.12 -18.6 / 49.4	0.75 SE 0.15 -10.0 / 34.8	0.61 SE 0.35 -2.6 / 5.1




Recurrence rates (% / year) and logrank analyses

	Years 0 – 4	Years 5 – 9	Year 10+
Polychemo.	7.52 (212 / 2821)	2.50 (42 / 1683)	2.49 (28 / 1126)
Control	11.31 (296 / 2618)	2.96 (40 / 1353)	3.08 (27 / 877)
Rate ratio, from (O-E) / V	0.62 SE 0.08 -48.5 / 103.0	0.88 SE 0.22 -2.3 / 18.1	0.93 SE 0.31 -0.7 / 9.9




Death rates (% / year: total rate – rate in women without recurrence) & logrank analyses

	Years 0 – 4	Years 5 – 9	Year 10+
Polychemo.	4.78 (5.17 – 0.39)	2.34 (3.35 – 1.01)	1.15 (2.36 – 1.21)
Control	6.31 (6.73 – 0.42)	3.10 (4.28 – 1.18)	1.53 (3.79 – 2.26)
Rate ratio, from (O–E) / V	0.74 SE 0.10 –22.0 / 73.6	0.74 SE 0.18 –7.3 / 24.2	0.68 SE 0.25 –4.1 / 10.6




Death rates (% / year) and logrank analyses

	Years 0 – 4	Years 5 – 9	Year 10+
<b>Polychemo.</b>	5.17 (159 / 3078)	3.35 (64 / 1913)	2.36 (34 / 1439)
<b>Control</b>	6.73 (205 / 3046)	4.28 (72 / 1682)	3.79 (46 / 1215)
<b>Rate ratio, from (O-E) / V</b>	0.76 SE 0.10 -21.8 / 77.7	0.72 SE 0.16 -9.7 / 29.4	0.77 SE 0.23 -3.9 / 14.8




Recurrence rates (% / year) and logrank analyses

	Years 0 – 4	Years 5 – 9	Year 10+
Polychemo.	5.53 (1410 / 25516)	5.12 (592 / 11561)	4.15 (95 / 2291)
Control	6.86 (1350 / 19692)	4.63 (401 / 8661)	5.05 (93 / 1843)
Rate ratio, from (O-E) / V	0.78 SE 0.04 -144.8 / 587.8	1.07 SE 0.07 14.3 / 213.8	0.85 SE 0.14 -6.9 / 41.6



Death rates (% / year: total rate – rate in women without recurrence) & logrank analyses


	Years 0 – 4	Years 5 – 9	Year 10+
Polychemo.	2.76 (3.39 – 0.63)	3.92 (5.07 – 1.15)	3.54 (6.48 – 2.94)
Control	3.18 (3.88 – 0.70)	4.16 (5.60 – 1.44)	3.76 (6.73 – 2.97)
Rate ratio, from (O-E) / V	0.85 SE 0.05 -55.6 / 339.2	0.92 SE 0.06 -18.8 / 236.4	0.99 SE 0.13 -0.7 / 61.6



Death rates (% / year) and logrank analyses


	Years 0 – 4	Years 5 – 9	Year 10+
Polychemo.	3.39 (924 / 27235)	5.07 (689 / 13601)	6.48 (188 / 2901)
Control	3.88 (842 / 21716)	5.60 (586 / 10470)	6.73 (163 / 2423)
Rate ratio, from (O-E) / V	0.86 SE 0.05 -56.9 / 387.7	0.90 SE 0.06 -29.6 / 278.6	1.01 SE 0.11 0.6 / 77.3






Recurrence rates (% / year) and logrank analyses

	Years 0 - 4	Years 5 - 9	Year 10+
Anthracycline	7.80 (2136 / 27371)	3.41 (396 / 11607)	2.71 (48 / 1770)
CMF	8.38 (1945 / 23211)	3.68 (325 / 8822)	2.80 (25 / 892)
Rate ratio, from (O-E) / V	0.89 SE 0.03 -101.8 / 853.6	0.89 SE 0.07 -19.0 / 160.2	1.04 SE 0.26 0.7 / 15.4




Death rates (% / year: total rate – rate in women without recurrence) & logrank analyses

	Years 0 – 4	Years 5 – 9	Year 10+
Anthracycline	4.23 (4.44 – 0.21)	3.33 (3.67 – 0.34)	2.25 (2.88 – 0.63)
CMF	4.82 (5.01 – 0.19)	3.50 (3.86 – 0.36)	3.46 (4.27 – 0.81)
Rate ratio, from (O–E) / V	0.83 SE 0.04 –100.2 / 554.1	0.89 SE 0.07 –22.6 / 186.8	0.64 SE 0.18 –9.0 / 20.1




Death rates (% / year) and logrank analyses

	Years 0 – 4	Years 5 – 9	Year 10+
Anthracycline	4.44 (1344 / 30261)	3.67 (506 / 13778)	2.88 (64 / 2224)
CMF	5.01 (1295 / 25847)	3.86 (407 / 10552)	4.27 (50 / 1172)
Rate ratio, from (O-E) / V	0.85 SE 0.04 -96.2 / 577.6	0.90 SE 0.07 -22.3 / 203.1	0.66 SE 0.17 -10.0 / 24.0




N.B: 95% of the data in the 'longer' vs. 'shorter' comparisons and 62% of the data in the anthracycline vs. CMF comparisons are from N+ patients



N.B: 95% of the data in the 'longer' vs. 'shorter' comparisons and 62% of the data in the anthracycline vs. CMF comparisons are from N+ patients


Denominator: number entering time period


18:04:20 20 February 2003  
Not for publication or citation




N.B: 95% of the data in the 'longer' vs. 'shorter' comparisons and 62% of the data in the anthracycline vs. CMF comparisons are from N+ patients  
Denominator: number entering time period


18:04:59 20 February 2003  
Not for publication or citation













Heterogeneity between effects in ER+ disease  
of different tamoxifen durations:  $\chi^2_1 = 23.2$ ;  $2p < 0.00001$

Heterogeneity between effects in PR+ disease  
of different tamoxifen durations:  $\chi^2_1 = 7.1$ ;  $2p = 0.008$




Heterogeneity between effects in ER+ disease  
of different tamoxifen durations:  $\chi_1^2 = 14.5$ ;  $2p = 0.0001$

Heterogeneity between effects in PR+ disease  
of different tamoxifen durations:  $\chi_1^2 = 6.7$ ;  $2p = 0.009$




Heterogeneity between effects in ER+ disease  
of different tamoxifen durations:  $\chi^2_1 = 8.2$ ;  $2p = 0.004$

Heterogeneity between effects in PR+ disease  
of different tamoxifen durations:  $\chi^2_1 = 4.7$ ;  $2p = 0.03$




Recurrence rates (% / year) and logrank analyses

	Years 0 – 4	Years 5 – 9	Years 10 – 14	Year 15+
Tamoxifen	3.41 (794 / 23311)	2.63 (422 / 16053)	2.42 (162 / 6706)	3.96 (34 / 858)
Control	6.13 (1317 / 21472)	3.52 (473 / 13456)	2.36 (127 / 5383)	3.46 (24 / 693)
Rate ratio, from	0.53 SE 0.03	0.69 SE 0.06	1.01 SE 0.12	1.01 SE 0.29
(O-E) / V	-309.2 / 482.9	-76.1 / 204.9	0.6 / 65.8	0.1 / 11.9




Death rates (% / year: total rate – rate in women without recurrence) & logrank analyses

	Years 0 – 4	Years 5 – 9	Years 10 – 14	Year 15+
Tamoxifen	1.72 (2.21 – 0.49)	2.22 (3.21 – 0.99)	1.82 (3.56 – 1.74)	2.34 (4.54 – 2.20)
Control	2.42 (2.92 – 0.50)	3.17 (4.19 – 1.02)	2.32 (4.03 – 1.71)	2.41 (3.21 – 0.80)
Rate ratio, from	0.69 SE 0.05	0.65 SE 0.05	0.74 SE 0.10	0.83 SE 0.26
(O–E) / V	–88.4 / 235.3	–94.5 / 221.2	–22.1 / 74.9	–2.2 / 11.9




Death rates (% / year) and logrank analyses

	Years 0 – 4	Years 5 – 9	Years 10 – 14	Year 15+
Tamoxifen	2.21 (540 / 24434)	3.21 (565 / 17613)	3.56 (273 / 7665)	4.54 (56 / 1233)
Control	2.92 (695 / 23792)	4.19 (690 / 16463)	4.03 (273 / 6782)	3.21 (34 / 1059)
Rate ratio, from	0.73 SE 0.05	0.71 SE 0.05	0.85 SE 0.08	1.29 SE 0.26
(O-E) / V	-90.2 / 289.3	-98.0 / 291.5	-19.6 / 124.4	4.8 / 18.9



\* Isolated contralateral recurrence as first event. (N.B. contralateral analyses in Table 3 and its Appendix are more complete, as they include additional trials).





Category	Deaths/women Allocated tamoxifen	Deaths/women Allocated control	Logrank O-E	Variance of O-E	Ratio of annual death rates Tamoxifen : Control
----------	--	--------------------------------------	----------------	--------------------	--

**(a) Dose of tamoxifen ( $\chi^2_1 = 1.2$ ;  $2p > 0.1$ ; NS)**

20 mg/day	861/3550 (24.3%)	1012/3530 (28.7%)	-108.6	439.0	0.78 (SE 0.04)
30-40 mg/day	573/1675 (34.2%)	680/1631 (41.7%)	-94.4	285.4	0.72 (SE 0.05)

**(b) Presence or absence of cytotoxics ( $\chi^2_2 = 4.3$ ;  $p > 0.1$ ; NS)**

CTX with Tam vs CTX alone	177/488 (36.3%)	221/462 (47.8%)	-43.1	88.9	0.62 (SE 0.08)
CTX then Tam vs CTX alone	170/1204 (14.1%)	212/1176 (18.0%)	-24.9	92.5	0.76 (SE 0.09)
Tam alone vs Nil (no adjuvant)	1067/3533 (30.8%)	1259/3523 (35.7%)	-135.0	543.0	0.78 (SE 0.04)

**(c) Entry age (trend  $\chi^2_1 = 0.5$ ;  $2p > 0.1$ ; NS)**

Age < 40	80/417 (19.2%)	122/398 (30.7%)	-21.1	46.1	0.63 (SE 0.12)
40 - 49	198/1119 (17.7%)	234/1139 (20.5%)	-19.5	99.6	0.82 (SE 0.09)
50 - 59	419/1591 (26.3%)	451/1535 (29.4%)	-33.7	196.3	0.84 (SE 0.07)
60 - 69	617/1822 (33.9%)	730/1789 (40.8%)	-94.8	303.7	0.73 (SE 0.05)
70+	120/266 (45.1%)	155/286 (54.2%)	-22.9	53.5	0.65 (SE 0.11)
Age unknown	0/10	0/14			

**(d) Menopausal status ( $\chi^2_1 = 0.6$ ;  $2p > 0.1$ ; NS)**

Pre-/peri-menopausal	276/1489 (18.5%)	336/1544 (21.8%)	-31.5	146.8	0.81 (SE 0.07)
Post-menopausal	1108/3471 (31.9%)	1282/3335 (38.4%)	-160.6	555.3	0.75 (SE 0.04)
Unknown	50/265 (18.9%)	74/282 (26.2%)	-12.6	29.5	0.65 (SE 0.15)

**(e) Tumour differentiation (trend  $\chi^2_1 = 5.0$ ;  $2p = 0.03$ )**

Good	27/181 (14.9%)	20/158 (12.7%)	2.1	10.6	
Moderate	80/351 (22.8%)	101/346 (29.2%)	-19.7	41.8	0.62 (SE 0.12)
Poor	17/103 (16.5%)	42/123 (34.1%)	-9.9	13.2	0.47 (SE 0.19)
Unknown	1310/4590 (28.5%)	1529/4534 (33.7%)	-170.4	667.6	0.77 (SE 0.03)

**(f) Tumour size (N- only) (trend  $\chi^2_1 = 0.1$ ;  $2p > 0.1$ ; NS)**

< 2 cm	336/1943 (17.3%)	432/1950 (22.2%)	-52.2	186.1	0.76 (SE 0.06)
2 - 5 cm	272/1071 (25.4%)	310/1032 (30.0%)	-33.0	138.6	0.79 (SE 0.08)
> 5 cm	11/50 (22.0%)	16/58 (27.6%)	-2.3	6.2	
Unknown	197/556 (35.4%)	215/584 (36.8%)	-11.0	95.6	0.89 (SE 0.10)

**(g) Nodal status ( $\chi^2_1 = 2.5$ ;  $2p > 0.1$ ; NS)**

N-	816/3620 (22.5%)	973/3624 (26.8%)	-96.5	429.4	0.80 (SE 0.04)
N+	617/1597 (38.6%)	716/1529 (46.8%)	-103.1	300.6	0.71 (SE 0.05)
Unknown	1/8	3/8	-1.4	0.7	

**(h) Strength of ER positivity ( $\chi^2_1 = 3.5$ ;  $2p = 0.06$ )**

ER+, not ++	704/2718 (25.9%)	824/2643 (31.2%)	-89.0	358.7	0.78 (SE 0.05)
ER++	439/1487 (29.5%)	559/1463 (38.2%)	-93.4	230.3	0.67 (SE 0.05)
ER unknown	291/1020 (28.5%)	309/1055 (29.3%)	-20.7	135.4	0.86 (SE 0.08)

**(i) PR status (in ER+) ( $\chi^2_1 = 0.0$ ;  $2p > 0.1$ ; NS)**

PR-poor, ER+	304/983 (30.9%)	387/987 (39.2%)	-49.1	161.1	0.74 (SE 0.07)
PR+, ER+	672/2906 (23.1%)	837/2839 (29.5%)	-109.4	361.3	0.74 (SE 0.05)
PR or ER unknown	458/1336 (34.3%)	468/1335 (35.1%)	-40.8	205.2	0.82 (SE 0.06)


**(j) Period of follow-up (trend  $\chi^2_1 = 1.6$ ;  $p > 0.1$ ; NS)**

Years 0-1 *	152/5225 (2.9%)	186/5161 (3.6%)	-19.2	79.5	0.78 (SE 0.10)
Years 2-4 *	388/4996 (7.8%)	509/4886 (10.4%)	-70.9	209.9	0.71 (SE 0.06)
Years 5-9 *	565/4476 (12.6%)	690/4257 (16.2%)	-98.0	291.5	0.71 (SE 0.05)
Year 10+ *	329/2409 (13.7%)	307/2185 (14.1%)	-14.8	143.3	0.90 (SE 0.08)

\* Denominator: number entering time period


<b>Total</b>	<b>1434/5225 (27.4%)</b>	<b>1692/5161 (32.8%)</b>	<b>-203.0</b>	<b>724.4</b>	<b>0.756 (SE 0.032) 2p &lt; 0.00001</b>
--------------	------------------------------	------------------------------	---------------	--------------	---






Recurrence rates (% / year) and logrank analyses

	Years 0 – 4	Years 5 – 9	Year 10+
Tamoxifen	3.52 (244 / 6936)	2.69 (114 / 4245)	1.98 (30 / 1515)
Control	5.84 (382 / 6541)	3.34 (123 / 3688)	1.91 (23 / 1206)
Rate ratio, from (O-E) / V	0.58 SE 0.06 -79.3 / 144.8	0.78 SE 0.12 -13.8 / 55.8	1.09 SE 0.30 1.0 / 12.1




Death rates (% / year: total rate – rate in women without recurrence) & logrank analyses

	Years 0 – 4	Years 5 – 9	Year 10+
Tamoxifen	1.62 (1.78 – 0.16)	2.22 (2.50 – 0.28)	1.10 (1.60 – 0.10)
Control	2.26 (2.37 – 0.11)	3.00 (3.14 – 0.14)	2.19 (2.22 – 0.47)
Rate ratio, from (O–E) / V	0.69 SE 0.10 –24.4 / 67.0	0.72 SE 0.11 –19.0 / 57.7	0.57 SE 0.21 –7.6 / 13.5




Death rates (% / year) and logrank analyses

	Years 0 – 4	Years 5 – 9	Year 10+
Tamoxifen	1.78 (130 / 7313)	2.50 (118 / 4711)	1.60 (30 / 1871)
Control	2.37 (171 / 7226)	3.14 (142 / 4518)	2.66 (43 / 1616)
Rate ratio, from (O-E) / V	0.73 SE 0.10 -22.7 / 71.5	0.78 SE 0.11 -15.4 / 61.6	0.67 SE 0.20 -6.7 / 16.7




Recurrence rates (% / year) and logrank analyses

	Years 0 – 4	Years 5 – 9	Year 10+
Tamoxifen	2.36 (389 / 16487)	1.89 (230 / 12163)	2.16 (134 / 6211)
Control	4.51 (705 / 15643)	2.85 (304 / 10670)	2.07 (108 / 5209)
Rate ratio, from (O-E) / V	0.52 SE 0.05 -169.7 / 260.3	0.65 SE 0.07 -55.1 / 128.3	1.03 SE 0.13 1.6 / 57.1



Death rates (% / year: total rate – rate in women without recurrence) & logrank analyses


	Years 0 – 4	Years 5 – 9	Year 10+
Tamoxifen	1.76 (2.39 – 0.63)	2.22 (3.46 – 1.24)	2.12 (4.25 – 2.13)
Control	2.49 (3.16 – 0.67)	3.23 (4.58 – 1.35)	2.38 (4.23 – 1.85)
Rate ratio, from (O–E) / V	0.68 SE 0.06 –65.7 / 170.5	0.64 SE 0.06 –73.0 / 165.5	0.83 SE 0.10 –14.4 / 75.1



Death rates (% / year) and logrank analyses


	Years 0 – 4	Years 5 – 9	Year 10+
Tamoxifen	2.39 (410 / 17134)	3.46 (447 / 12916)	4.25 (299 / 7039)
Control	3.16 (524 / 16577)	4.58 (548 / 11953)	4.23 (264 / 6240)
Rate ratio, from (O-E) / V	0.73 SE 0.06 -69.7 / 220.2	0.71 SE 0.06 -80.2 / 232.3	0.95 SE 0.09 -6.2 / 128.6






Recurrence rates (% / year) and logrank analyses

	Years 0 – 4	Years 5 – 9	Year 10+
Tamoxifen	2.36 (389 / 16487)	1.89 (230 / 12163)	2.16 (134 / 6211)
Control	4.51 (705 / 15643)	2.85 (304 / 10670)	2.07 (108 / 5209)
Rate ratio, from (O-E) / V	0.52 SE 0.05 -169.7 / 260.3	0.65 SE 0.07 -55.1 / 128.3	1.03 SE 0.13 1.6 / 57.1




Death rates (% / year: total rate – rate in women without recurrence) & logrank analyses

	Years 0 – 4	Years 5 – 9	Year 10+
Tamoxifen	0.97 (1.47 – 0.50)	1.50 (2.56 – 1.06)	1.30 (3.14 – 1.84)
Control	1.44 (1.94 – 0.50)	2.19 (3.22 – 1.03)	1.93 (3.44 – 1.51)
Rate ratio, from (O–E) / V	0.67 SE 0.08 –39.7 / 100.6	0.70 SE 0.08 –43.5 / 123.2	0.70 SE 0.11 –21.4 / 59.3




Death rates (% / year) and logrank analyses

	Years 0 – 4	Years 5 – 9	Year 10+
Tamoxifen	1.47 (252 / 17158)	2.56 (338 / 13197)	3.14 (226 / 7202)
Control	1.94 (331 / 17030)	3.22 (413 / 12811)	3.44 (229 / 6648)
Rate ratio, from (O-E) / V	0.75 SE 0.07 -40.9 / 140.6	0.79 SE 0.07 -43.4 / 181.3	0.89 SE 0.09 -12.2 / 107.5




Recurrence rates (% / year) and logrank analyses

	Years 0 – 4	Years 5 – 9	Year 10+
Tamoxifen	5.94 (404 / 6798)	4.97 (192 / 3866)	4.55 (62 / 1362)
Control	10.53 (611 / 5800)	6.04 (167 / 2767)	4.89 (43 / 879)
Rate ratio, from (O-E) / V	0.53 SE 0.05 -142.9 / 225.6	0.80 SE 0.10 -17.6 / 79.0	0.97 SE 0.21 -0.6 / 22.6




Death rates (% / year: total rate – rate in women without recurrence) & logrank analyses

	Years 0 – 4	Years 5 – 9	Year 10+
Tamoxifen	3.50 (3.96 – 0.46)	4.38 (5.16 – 0.78)	4.42 (6.06 – 1.64)
Control	4.92 (5.41 – 0.49)	6.57 (7.55 – 0.98)	4.51 (6.46 – 1.95)
Rate ratio, from (O–E) / V	0.69 SE 0.07 –50.9 / 136.7	0.62 SE 0.08 –47.1 / 99.3	0.99 SE 0.18 –0.4 / 29.3




Death rates (% / year) and logrank analyses

	Years 0 – 4	Years 5 – 9	Year 10+
Tamoxifen	3.96 (287 / 7252)	5.16 (227 / 4396)	6.06 (103 / 1701)
Control	5.41 (364 / 6733)	7.55 (274 / 3630)	6.46 (78 / 1207)
Rate ratio, from (O-E) / V	0.71 SE 0.07 -52.1 / 150.9	0.64 SE 0.08 -50.7 / 111.9	0.99 SE 0.16 -0.4 / 37.8



Recurrence rates (% / year) and logrank analyses


	Years 0 – 4	Years 5 – 9	Year 10+
Tamoxifen	3.13 (492 / 15712)	2.36 (284 / 12017)	2.44 (171 / 6997)
Control	6.01 (870 / 14485)	3.40 (344 / 10105)	2.41 (138 / 5725)
Rate ratio, from (O-E) / V	0.50 SE 0.04 -217.3 / 311.9	0.64 SE 0.07 -64.6 / 143.7	1.01 SE 0.12 0.5 / 70.5



Death rates (% / year: total rate – rate in women without recurrence) & logrank analyses


	Years 0 – 4	Years 5 – 9	Year 10+
Tamoxifen	1.59 (2.21 – 0.62)	2.04 (3.21 – 1.17)	1.76 (3.67 – 1.91)
Control	2.27 (2.88 – 0.61)	2.93 (4.08 – 1.15)	2.22 (3.88 – 1.66)
Rate ratio, from (O–E) / V	0.68 SE 0.07 –56.5 / 148.2	0.65 SE 0.07 –66.6 / 154.7	0.76 SE 0.10 –20.9 / 77.8






Death rates (% / year) and logrank analyses

	Years 0 – 4	Years 5 – 9	Year 10+
Tamoxifen	2.21 (364 / 16443)	3.21 (421 / 13100)	3.67 (302 / 8222)
Control	2.88 (465 / 16141)	4.08 (507 / 12416)	3.88 (287 / 7392)
Rate ratio, from (O-E) / V	0.75 SE 0.06 -56.9 / 193.6	0.74 SE 0.06 -66.3 / 215.7	0.92 SE 0.08 -11.8 / 133.6




Recurrence rates (% / year) and logrank analyses

	Years 0 – 4	Years 5 – 9	Year 10+
Tamoxifen	3.99 (302 / 7561)	3.44 (138 / 4007)	4.71 (25 / 531)
Control	6.43 (447 / 6953)	3.88 (129 / 3324)	4.15 (13 / 313)
Rate ratio, from (O-E) / V	0.58 SE 0.06 -91.8 / 171.0	0.83 SE 0.12 -11.5 / 61.3	1.02 SE 0.38 0.2 / 7.3




Death rates (% / year: total rate – rate in women without recurrence) & logrank analyses

	Years 0 – 4	Years 5 – 9	Year 10+
Tamoxifen	1.98 (2.21 – 0.23)	2.76 (3.21 – 0.45)	3.86 (4.23 – 0.37)
Control	2.76 (3.02 – 0.26)	3.92 (4.55 – 0.63)	4.63 (4.95 – 0.32)
Rate ratio, from (O–E) / V	0.69 SE 0.09 –31.9 / 87.1	0.66 SE 0.10 –27.9 / 66.5	0.69 SE 0.28 –3.3 / 9.0




Death rates (% / year) and logrank analyses


	Years 0 – 4	Years 5 – 9	Year 10+
Tamoxifen	2.21 (176 / 7957)	3.21 (144 / 4484)	4.23 (27 / 639)
Control	3.02 (230 / 7619)	4.55 (183 / 4021)	4.95 (20 / 404)
Rate ratio, from (O-E) / V	0.71 SE 0.09 -33.3 / 95.8	0.66 SE 0.09 -31.7 / 75.8	0.74 SE 0.28 -3.0 / 9.7




\* More than 4 years of tamoxifen at randomisation.




\* More than 4 years of tamoxifen at randomisation.  
Denominator: number entering time period





\* More than 4 years of tamoxifen at randomisation.  
Denominator: number entering time period













Recurrence rates (% / year) and logrank analyses

	Years 0 – 4	Years 5 – 9	Years 10 – 14	Year 15+
Abl./suppr.	6.37 (960 / 15067)	4.54 (255 / 5611)	2.40 (55 / 2293)	1.49 (41 / 2743)
Control	7.33 (1057 / 14424)	5.18 (249 / 4810)	2.73 (44 / 1609)	2.08 (36 / 1730)
Rate ratio, from (O-E) / V	0.82 SE 0.04 -88.0 / 446.0	0.91 SE 0.09 -10.4 / 115.5	0.92 SE 0.20 -1.8 / 22.0	0.64 SE 0.20 -7.0 / 15.5




Death rates (% / year: total rate – rate in women without recurrence) & logrank analyses

	Years 0 – 4	Years 5 – 9	Years 10 – 14	Year 15+
Abl./suppr.	3.65 (3.76 – 0.11)	4.29 (4.49 – 0.20)	2.35 (3.07 – 0.72)	0.87 (2.87 – 2.00)
Control	3.79 (3.86 – 0.07)	4.74 (4.92 – 0.18)	2.73 (3.39 – 0.66)	2.16 (4.07 – 1.91)
Rate ratio, from (O-E) / V	0.90 SE 0.06 –28.7 / 272.0	0.93 SE 0.08 –10.0 / 129.0	0.87 SE 0.18 –3.8 / 27.1	0.41 SE 0.15 –17.9 / 19.9




Death rates (% / year) and logrank analyses

	Years 0 – 4	Years 5 – 9	Years 10 – 14	Year 15+
Abl./suppr.	3.76 (609 / 16191)	4.49 (289 / 6441)	3.07 (78 / 2540)	2.87 (89 / 3101)
Control	3.86 (612 / 15875)	4.92 (287 / 5828)	3.39 (65 / 1918)	4.07 (88 / 2161)
Rate ratio, from	0.91 SE 0.06	0.92 SE 0.08	0.88 SE 0.17	0.66 SE 0.13
(O-E) / V	-26.9 / 278.1	-10.8 / 133.0	-4.0 / 31.9	-16.0 / 38.1




Recurrence rates (% / year) and logrank analyses

	Years 0 – 4	Years 5 – 9	Years 10 – 14	Year 15+
Abl./suppr.	7.23 (1581 / 21871)	4.58 (390 / 8520)	3.12 (114 / 3657)	2.18 (87 / 3992)
Control	7.98 (1628 / 20401)	5.17 (370 / 7156)	3.03 (81 / 2674)	2.25 (63 / 2794)
Rate ratio, from	0.86 SE 0.04	0.89 SE 0.07	0.99 SE 0.15	0.80 SE 0.17
(O-E) / V	-108.6 / 695.5	-19.2 / 170.0	-0.4 / 41.3	-6.4 / 29.3



Death rates (% / year: total rate – rate in women without recurrence) & logrank analyses

	Years 0 – 4	Years 5 – 9	Years 10 – 14	Year 15+
Abl./suppr.	4.32 (1026 / 23749)	4.28 (422 / 9850)	3.38 (141 / 4169)	2.30 (107 / 4658)
Control	4.33 (976 / 22521)	5.00 (434 / 8688)	3.56 (115 / 3226)	2.62 (93 / 3555)
Rate ratio, from	0.92 SE 0.05	0.86 SE 0.07	0.86 SE 0.12	0.73 SE 0.13
(O-E) / V	-35.8 / 446.7	-29.9 / 193.8	-8.4 / 55.2	-12.7 / 41.0




Death rates (% / year) and logrank analyses

	Years 0 - 4	Years 5 - 9	Years 10 - 14	Year 15+
Abl./suppr.	4.45 (1057 / 23749)	4.60 (453 / 9850)	4.03 (168 / 4169)	4.14 (193 / 4658)
Control	4.45 (1002 / 22521)	5.29 (460 / 8688)	4.28 (138 / 3226)	4.67 (166 / 3555)
Rate ratio, from	0.93 SE 0.04	0.86 SE 0.06	0.88 SE 0.12	0.86 SE 0.11
(O-E) / V	-34.8 / 460.4	-30.8 / 207.0	-8.4 / 66.5	-11.5 / 77.1




Annual cancer mortality / 100 000 women, ages 35-69\*




\*Mean of annual rates in the component 5-year age groups

Source: WHO mortality & UN population estimates




\*Mean of annual rates in the component 5-year age groups

Source: WHO mortality & UN population estimates




\*Mean of annual rates in the component 5-year age groups

Source: WHO mortality & UN population estimates




\*Mean of annual rates in the component 5-year age groups

Source: WHO mortality & UN population estimates




\*Mean of annual rates in the component 5-year age groups

Source: WHO mortality & UN population estimates




\*Mean of annual rates in the component 5-year age groups

Source: WHO mortality & UN population estimates



\*Mean of annual rates in the component 5-year age groups


Source: WHO mortality & UN population estimates



\*Mean of annual rates in the component 5-year age groups


Source: WHO mortality & UN population estimates






\*Mean of annual rates in the component 5-year age groups

Source: WHO mortality & UN population estimates



\*Mean of annual rates in the component 5-year age groups

Source: WHO mortality & UN population estimates




\*Mean of annual rates in the component 5-year age groups

Source: WHO mortality & UN population estimates


# RUSSIAN FEDERATION

1980-2002




\*Mean of annual rates in the component 5-year age groups

Source: WHO mortality & UN population estimates




\*Mean of annual rates in the component 5-year age groups

Source: WHO mortality & UN population estimates



\*Mean of annual rates in the component 5-year age groups

Source: WHO mortality & UN population estimates



\*Mean of annual rates in the component 5-year age groups

Source: WHO mortality & UN population estimates